PATENT CLAIM ANALYSIS

Application Number: 16066427
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "234200"]

Abstract:
The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.

Claim (Index 8):
The compound or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug according to  claim 5 , wherein\n R 3  is selected from the group consisting of: fluoro, chloro; benzyloxy, m-fluorobenzyloxy, o-fluorobenzyloxy, p-fluorobenzyloxy, 3,4-difluorobenzyloxy, 2,5-difluorobenzyloxy; pyridin-2-ylmethoxy, 6-methylpyridin-2-ylmethoxy, 4-methoxy-3,5-dimethylpyridin-2-ylmethoxy, 6-methylpyridin-3-ylmethoxy, thiazol-2-ylmethoxy, imidazol-2-ylmethoxy, and (1-methyl-1H-imidazol-2-yl)methoxy.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 94.0
- Lexical Diversity: 1.71429
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16062399', '13319079', '15534838', '14521766', '15544676']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8365273878792351
- 35 USC 102 Novelty (BERT): 0.6268246011124867
- Combined Prediction Score: 0.8155571092025603
- Mean Citation Score: 419.36657
- Max Citation Score: 604.61755
- Similarity Product: 538.6715155697286

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test